Chemically modified RNA induces osteogenesis of stem cells and human tissue explants as well as accelerates bone healing in rats

Biomaterials

Volumn 87, Issue , 2016, Pages 131-146

  Balmayor, Elizabeth R ^a,b,c   Geiger, Johannes P ^b   Aneja, Manish K ^b   Berezhanskyy, Taras ^a,b   Utzinger, Maximilian ^b   Mykhaylyk, Olga ^a,b   Rudolph, Carsten ^b   Plank, Christian ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ETHRIS GMBH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bone healing; Bone morphogenetic protein; Chemically modified mRNA; Genetically modified fat graft; In vitro osteogenesis; MRNA delivery

Indexed keywords

COLLAGEN; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENES; NUCLEIC ACIDS; PHOSPHATASES; PROTEINS; RNA; STEM CELLS; TISSUE;

BONE HEALING; BONE MORPHOGENETIC PROTEINS; CHEMICALLY MODIFIED; GENETICALLY MODIFIED; MRNA DELIVERY; OSTEOGENESIS;

BONE;

ALIZARIN RED S; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN TYPE 1; LIPOPLEX; MESSENGER RNA; OSTEOCALCIN; OSTEOPONTIN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; BMP2 PROTEIN, HUMAN;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEVELOPMENT; BONE REGENERATION; CONTROLLED STUDY; EXPLANT; FOLLOW UP; FRACTURE HEALING; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO GENE TRANSFER; IN VITRO STUDY; MINERALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; STEM CELL; UPREGULATION; ANIMAL; CELL CULTURE; CHEMISTRY; CYTOLOGY; FEMUR; GENETIC TRANSFECTION; GENETICS; INJURIES; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE REGENERATION; CELLS, CULTURED; FEMUR; GENETIC THERAPY; HUMANS; MALE; OSTEOGENESIS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STEM CELLS; TRANSFECTION;

EID: 84958976320     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.02.018     Document Type: Article

References (51)

1. Tanner K.E. Bioactive ceramic-reinforced composites for bone augmentation. J. R. Soc. Interface 2010, 5:541-557.
2. Tanner K.E. Bioactive composites for bone tissue engineering. Proc. Inst. Mech. Eng. H. 2010, 224:1359-1372.
3. Mourino V., Cattalini J.P., Roether J.A., Dubey P., Roy I., Boccaccini A.R. Composite polymer-bioceramic scaffolds with drug delivery capability for bone tissue engineering. Expert Opin. Drug Deliv. 2013, 10:1353-1365.
4. Romagnoli C., D'Asta F., Brandi M.L. Drug delivery using composite scaffolds in the context of bone tissue engineering. Clin. Cases Min. Bone Metab. 2013, 10:155-161.
5. Reichert J.C., Cipitria A., Epari D.R., Saifzadeh S., Krishnakanth P., Berner A., et al. A tissue engineering solution for segmental defect regeneration in load-bearing long bones. Sci. Transl. Med. 2012, 4:141-193.
6. Aspenberg P. Special review: accelerating fracture repair in humans: a reading of old experiments and recent clinical trials. Bonekey Rep. 2013, 2:244.
7. Carragee E.J., Hurwitz E.L., Weiner B.K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011, 11:471-491.
8. Li H., Johnson N.R., Usas A., Lu A., Poddar M., Wang Y., et al. Sustained release of bone morphogenetic protein 2 via coacervate improves the osteogenic potential of muscle-derived stem cells. Stem Cells Transl. Med. 2013, 2:667-677.
9. Santo V.E., Gomes M.E., Mano J.F., Reis R.L. Controlled release strategies for bone, cartilage, and osteochondral engineering-Part I: recapitulation of native tissue healing and variables for the design of delivery systems. Tissue Eng. Part B Rev. 2013, 19:308-326.
10. Martino MM, Briquez PS, Maruyama K, Hubbell JA. Extracellular matrix-inspired growth factor delivery systems for bone regeneration [published online ahead of print April 17, 2015]. Adv Drug Deliv Rev.
11. Martino M.M., Tortelli F., Mochizuki M., Traub S., Ben-David D., Kuhn G.A., et al. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci. Transl. Med. 2011, 3:100-189.
12. Kisiel M., Klar A.S., Ventura M., Buijs J., Mafina M.K., Cool S.M., et al. Complexation and sequestration of BMP-2 from an ECM mimetic hyaluronan gel for improved bone formation. PLoS One 2013, 8:e78551.
13. Evans C.H. Gene delivery to bone. Adv. Drug Deliv. Rev. 2012, 64:1331-1340.
14. Lu K., Xu L., Xia L., Zhang Y., Zhang X., Kaplan D.L., et al. An ectopic study of apatite-coated silk fibroin scaffolds seeded with AdBMP-2-modified canine bMSCs. J. Biomater. Sci. Polym. Ed. 2012, 23:509-526.
15. Chang S.C., Lin T.M., Chung H.Y., Chen P.K., Lin F.H., Lou J., et al. Large-scale bicortical skull bone regeneration using ex vivo replication-defective adenoviral-mediated bone morphogenetic protein-2 gene-transferred bone marrow stromal cells and composite biomaterials. Neurosurgery 2009, 65:75-81.
16. Park J., Ries J., Gelse K., Kloss F., von der Mark K., Wiltfang J., et al. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther. 2003, 10:1089-1098.
17. Van Tendeloo V.F., Ponsaerts P., Berneman Z.N. mRNA-based gene transfer as a tool for gene and cell therapy. Curr. Opin. Mol. Ther. 2007, 9:423-431.
18. Holtkamp S., Kreiter S., Selmi A., Simon P., Koslowski M., Huber C., et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 2006, 108:4009-4017.
19. Kormann M.S., Hasenpusch G., Aneja M.K., Nica G., Flemmer A.W., Herber-Jonat S., et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 2011, 29:154-157.
20. Mays L.E., Ammon-Treiber S., Mothes B., Alkhaled M., Rottenberger J., Muller-Hermelink E.S., et al. Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism. J. Clin. Investig. 2013, 123:1216-1228.
21. Mykhaylyk O., Sanchez-Antequera Y., Vlaskou D., Hammerschmid E., Anton M., Zelphati O., et al. Liposomal magnetofection. Liposomes, Methods in Molecular Biology 2010, 487-525. Humana Press-Springer, New York. V. Weissig (Ed.).
22. Mykhaylyk O., Sobisch T., Almstatter I., Sanchez-Antequera Y., Brandt S., Anton M., et al. Silica-iron oxide magnetic nanoparticles modified for gene delivery: a search for optimum and quantitative criteria. Pharm. Res. 2012, 29:1344-1365.
23. Balmayor E.R., Flicker M., Käser T., Saalmüller A., Erben R.G. Human placental alkaline phosphatase as a tracking marker for bone marrow mesenchymal stem cells. Biores Open Access 2013, 2:346-355.
24. Balmayor E.R., Flicker M., Käser T., Saalmüller A., Erben R.G. Human placental alkaline phosphatase as a tracking marker for bone marrow mesenchymal stem cells. Biores Open Access 2013, 2:346-355.
25. Cox W.G., Singer V.L. A high-resolution, fluorescence-based method for localization of endogenous alkaline phosphatase activity. J. Histochem Cytochem 1999, 47:1443-1456.
26. Evans C.H., Liu F.J., Glatt V., Hoyland J.A., Kirker-Head C., Walsh A., et al. Use of genetically modified muscle and fat grafts to repair defects in bone and cartilage. Eur. Cell Mater 2009, 18:96-111.
27. Puri V., Chakladar A., Virbasius J.V., Konda S., Powelka A.M., Chouinard M., et al. RNAi-based gene silencing in primary mouse and human adipose tissues. J. Lipid Res. 2007, 48:465-471.
28. Kunzelmann KH. KHKs ImageJ I/O Utilities. Downloaded February 2015. http://www.dent.med.uni-muenchen.de/%7Ekkunzelm/htdocs/6_software-imagej-import-export-utilities.html.
29. Doube M., Klosowski M.M., Arganda-Carreras I., Cordelieres F.P., Dougherty R.P., Jackson J.S., et al. BoneJ: free and extensible bone image analysis in ImageJ. Bone 2010, 47:1076-1079.
30. Schmid B., Schindelin J., Cardona A., Longair M., Heisenberg M. A high-level 3D visualization API for java and ImageJ. BMC Bioinforma. 2010, 11:274.
31. Plank C., Zelphati O., Mykhaylyk O. Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-progress and prospects. Adv. Drug Deliv. Rev. 2011, 63:1300-1331.
32. Demirkan N., Demirkan F., Aksoy A., Ozdemir M., Akman A. Local rhBMP-2 injection after drill-hole injury in rats: does it have systemic effects?. Int. J. Immunopathol. Pharmacol. 2014, 27:253-260.
33. Keibl C., Fügl A., Zanoni G., Tangl S., Wolbank S., Redl H., et al. Human adipose derived stem cells reduce callus volume upon BMP-2 administration in bone regeneration. Injury 2011, 42:814-820.
34. Tanaka M., Sakai A., Uchida S., Tanaka S., Nagashima M., Katayama T., et al. Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 2004, 34:940-948.
35. Lo K.W., Ashe K.M., Kan H.M., Laurencin C.T. The role of small molecules in musculoskeletal regeneration. Regen. Med. 2012, 7:535-549.
36. Chrastil J., Low J.B., Whang P.G., Patel A.A. Complications associated with the use of the recombinant human bone morphogenetic proteins for posterior interbody fusions of the lumbar spine. Spine 2013, 38:E1020-E1027.
37. Epstein N.E. Complications due to the use of BMP/INFUSE in spine surgery: the evidence continues to mount. Surg. Neurol. Int. 2013, 4:S343-S352.
38. FDA Public Health Notification: Life-threatening complications Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion Information Web Site. Accessed May 18, 2015. http://www.fda.gov/medicaldevices/safety/alertsandnotices/publichealthnotifications/ucm062000.htm.
39. Devine J.G., Dettori J.R., France J.C., Brodt E., McGuire R.A. The use of rhBMP in spine surgery: is there a cancer risk?. Evid. Based Spine Care J. 2012, 3:35-41.
40. Even J., Eskander M., Kang J. Bone morphogenetic protein in spine surgery: current and future uses. J. Am. Acad. Orthop. Surg. 2012, 20:547-552.
41. Deutsch H. High-dose bone morphogenetic protein-induced ectopic abdomen bone growth. Spine J. 2010, 10:e1-e4.
42. Elangovan S., Khorsand B., Do A.V., Hong L., Dewerth A., Kormann M., et al. Chemically modified RNA activated matrices enhance bone regeneration. J. Control. Release: Off. J. Control. Release Soc. 2015, 218:22-28.
43. Lakshmipathy U., Pelacho B., Sudo K., Linehan J.L., Coucouvanis E., Kaufman D.S., et al. Efficient transfection of embryonic and adult stem cells. Stem cells 2004, 22:531-543.
44. Hayashi O., Katsube Y., Hirose M., Ohgushi H., Ito H. Comparison of osteogenic ability of rat mesenchymal stem cells from bone marrow, periosteum, and adipose tissue. Calcif. Tissue Int. 2008, 82:238-247.
45. Im G.I., Shin Y.W., Lee K.B. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells?. Osteoarthr. Cartilage/OARS, Osteoarthr. Res. Soc. 2005, 13:845-853.
46. Evans C.H., Palmer G.D., Pascher A., Porter R., Kwong F.N., Gouze E., et al. Facilitated endogenous repair: making tissue engineering simple, practical, and economical. Tissue Eng. 2007, 13:1987-1993.
47. Dragoo J.L., Lieberman J.R., Lee R.S., Deugarte D.A., Lee Y., Zuk P.A., et al. Tissue-engineered bone from BMP-2-transduced stem cells derived from human fat. Plast. Reconstr. Surg. 2005, 115:1665-1673.
48. Kilkenny C., Browne W.J., Cuthill I.C., Emerson M., Altman D.G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010, 8:e1000412.
49. Balmayor E.R., van Griensven M. Gene therapy for bone engineering. Front. Bioeng. Biotechnol. 2015, 3:9.
50. Williams P.D., Ranjzad P., Kakar S.J., Kingston P.A. Development of viral vectors for use in cardiovascular gene therapy. Viruses 2010, 2:334-371.
51. Hu Y.-C. Viral gene therapy vectors, springerbriefs in bioengineering. Gene Therapy for Cartilage and Bone Tissue Engineering 2014, 17-32. Springer, New York. Y.-C. Hu (Ed.).